Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Inhibrx Biosciences (INBX) Debt to Equity (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Debt to Equity for 2 consecutive years, with $2.71 as the latest value for Q3 2025.

  • On a quarterly basis, Debt to Equity changed N/A to $2.71 in Q3 2025 year-over-year; TTM through Sep 2025 was $2.71, a N/A change, with the full-year FY2023 number at $4.76, changed N/A from a year prior.
  • Debt to Equity was $2.71 for Q3 2025 at Inhibrx Biosciences, up from $1.45 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $4.76 in Q4 2023 to a low of $1.04 in Q1 2025.